High-flow Nasal Cannula Oxygen Therapy for Ischemic Stroke Patients With Dysphagia and Obstructive Sleep Apnea

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04173767

Enrollment

Registered

2019-11-22

Start date

2018-02-01

Completion date

2019-01-31

Last updated

2019-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Infarction, Deglutition Disorders, Sleep Apnea, Obstructive

Brief summary

High flow nasal cannula (HFNC) ventilation therapy was found to improve the severity of obstructive sleep apnea in non-stroke subjects. The investigators hypothesized that HFNC might be effective in stroke patients with dysphagia who needed nasogastric tube feeding and can not receive continuous positive airway pressure ventilation for obstructive sleep apnea.

Interventions

DEVICEhigh flow nasal cannula ventilation

High-flow nasal cannula (HFNC) ventilation therapy: supply heated & humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* ischemic stroke patients with dysphagia and obstructive sleep apnea who need nasogastric tube feedings

Exclusion criteria

* congestive heart failure, unconsciousness, chronic obstructive pulmonary disease, intracranial hemorrhage or malignancy, and unstable medical and neurological conditions * central sleep apnea

Design outcomes

Primary

Measure	Time frame	Description
apnea-hypopnea index	once at polysomnography study night when receive high flow nasal cannula titration study	respiratory inductance plethysmography sum (RIPsum) without calibration to score apnea and hypopnea events (American Academy of Sleep Medicine alternative criteria)
oxyhemoglobin desaturation index	once at polysomnography study night when receive high flow nasal cannula titration study	number of times per hour of sleep that the blood's oxygen saturation level drops by ≥ 3% from baseline

Secondary

Measure	Time frame	Description
pulse wave velocity	baseline and 1 week after high flow nasal cannula therapy	velocity (m/s) measured by SphygmoCor CPV system
heart rate variability	baseline and 1 week after high flow nasal cannula therapy	measured by QHRV system (Medeia Ltd.)

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026